vs
Side-by-side financial comparison of Regeneron Pharmaceuticals (REGN) and Rocket Companies, Inc. (RKT). Click either name above to swap in a different company.
Regeneron Pharmaceuticals is the larger business by last-quarter revenue ($3.6B vs $2.7B, roughly 1.3× Rocket Companies, Inc.). Regeneron Pharmaceuticals runs the higher net margin — 20.2% vs 2.5%, a 17.6% gap on every dollar of revenue. On growth, Rocket Companies, Inc. posted the faster year-over-year revenue change (52.2% vs 19.0%). Regeneron Pharmaceuticals produced more free cash flow last quarter ($848.3M vs $-1.3B). Over the past eight quarters, Rocket Companies, Inc.'s revenue compounded faster (39.5% CAGR vs 0.8%).
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Rocket Companies, Inc., is an American fintech and homeownership services company. Founded by Dan Gilbert and based in Downtown Detroit, Michigan, the company is one of the largest mortgage lenders in the United States through its flagship subsidiary Rocket Mortgage. Its subsidiaries include Redfin, Forsalebyowner.com, and Rocket Money.
REGN vs RKT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.6B | $2.7B |
| Net Profit | $727.0M | $68.0M |
| Gross Margin | 89.6% | — |
| Operating Margin | 17.8% | 6.3% |
| Net Margin | 20.2% | 2.5% |
| Revenue YoY | 19.0% | 52.2% |
| Net Profit YoY | -10.1% | 100.8% |
| EPS (diluted) | $6.75 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.9B | $2.7B | ||
| Q3 25 | $3.8B | $1.6B | ||
| Q2 25 | $3.7B | $1.4B | ||
| Q1 25 | $3.0B | $1.0B | ||
| Q4 24 | $3.8B | $1.8B | ||
| Q3 24 | $3.7B | $646.9M | ||
| Q2 24 | $3.5B | $1.3B |
| Q1 26 | $727.0M | — | ||
| Q4 25 | $844.6M | $68.0M | ||
| Q3 25 | $1.5B | $-123.9M | ||
| Q2 25 | $1.4B | $-1.8M | ||
| Q1 25 | $808.7M | $-10.4M | ||
| Q4 24 | $917.7M | $33.9M | ||
| Q3 24 | $1.3B | $-22.0M | ||
| Q2 24 | $1.4B | $1.3M |
| Q1 26 | 89.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | -8.4% | ||
| Q2 24 | — | 47.4% |
| Q1 26 | 17.8% | — | ||
| Q4 25 | 22.7% | 6.3% | ||
| Q3 25 | 27.3% | -11.5% | ||
| Q2 25 | 29.4% | 1.8% | ||
| Q1 25 | 19.5% | -21.5% | ||
| Q4 24 | 26.1% | 38.1% | ||
| Q3 24 | 31.7% | -76.9% | ||
| Q2 24 | 30.2% | 14.8% |
| Q1 26 | 20.2% | — | ||
| Q4 25 | 21.7% | 2.5% | ||
| Q3 25 | 38.9% | -7.7% | ||
| Q2 25 | 37.9% | -0.1% | ||
| Q1 25 | 26.7% | -1.0% | ||
| Q4 24 | 24.2% | 1.9% | ||
| Q3 24 | 36.0% | -3.4% | ||
| Q2 24 | 40.4% | 0.1% |
| Q1 26 | $6.75 | — | ||
| Q4 25 | $7.78 | $0.10 | ||
| Q3 25 | $13.62 | $-0.06 | ||
| Q2 25 | $12.81 | $-0.01 | ||
| Q1 25 | $7.27 | $-0.08 | ||
| Q4 24 | $8.12 | $0.28 | ||
| Q3 24 | $11.54 | $-0.19 | ||
| Q2 24 | $12.41 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.7B |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $31.4B | $22.9B |
| Total Assets | $40.9B | $60.7B |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.6B | $2.7B | ||
| Q3 25 | $8.4B | $5.8B | ||
| Q2 25 | $7.5B | $5.1B | ||
| Q1 25 | $8.3B | $1.4B | ||
| Q4 24 | $9.0B | $1.3B | ||
| Q3 24 | $9.8B | $1.2B | ||
| Q2 24 | $9.8B | $1.3B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $31.4B | — | ||
| Q4 25 | $31.3B | $22.9B | ||
| Q3 25 | $31.0B | $8.9B | ||
| Q2 25 | $29.9B | $7.4B | ||
| Q1 25 | $29.4B | $8.6B | ||
| Q4 24 | $29.4B | $9.0B | ||
| Q3 24 | $29.3B | $8.4B | ||
| Q2 24 | $28.2B | $8.8B |
| Q1 26 | $40.9B | — | ||
| Q4 25 | $40.6B | $60.7B | ||
| Q3 25 | $40.2B | $33.6B | ||
| Q2 25 | $38.2B | $30.4B | ||
| Q1 25 | $37.5B | $25.3B | ||
| Q4 24 | $37.8B | $24.5B | ||
| Q3 24 | $37.4B | $25.1B | ||
| Q2 24 | $36.1B | $23.6B |
| Q1 26 | 0.06× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1B | $-1.2B |
| Free Cash FlowOCF − Capex | $848.3M | $-1.3B |
| FCF MarginFCF / Revenue | 23.5% | -47.2% |
| Capex IntensityCapex / Revenue | 6.4% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.48× | -18.08× |
| TTM Free Cash FlowTrailing 4 quarters | $4.1B | $-4.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $-1.2B | ||
| Q3 25 | $1.6B | $-50.3M | ||
| Q2 25 | $1.1B | $-1.9B | ||
| Q1 25 | $1.0B | $-797.0M | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $-1.3B | ||
| Q2 24 | $354.0M | $-122.3M |
| Q1 26 | $848.3M | — | ||
| Q4 25 | $922.0M | $-1.3B | ||
| Q3 25 | $1.4B | $-71.8M | ||
| Q2 25 | $925.4M | $-1.9B | ||
| Q1 25 | $815.8M | $-811.0M | ||
| Q4 24 | $1.1B | $1.8B | ||
| Q3 24 | $1.0B | $-1.4B | ||
| Q2 24 | $173.5M | $-138.3M |
| Q1 26 | 23.5% | — | ||
| Q4 25 | 23.7% | -47.2% | ||
| Q3 25 | 37.8% | -4.5% | ||
| Q2 25 | 25.2% | -137.2% | ||
| Q1 25 | 26.9% | -78.2% | ||
| Q4 24 | 28.1% | 103.1% | ||
| Q3 24 | 28.2% | -209.6% | ||
| Q2 24 | 4.9% | -10.6% |
| Q1 26 | 6.4% | — | ||
| Q4 25 | 6.4% | 1.5% | ||
| Q3 25 | 5.4% | 1.3% | ||
| Q2 25 | 6.0% | 1.1% | ||
| Q1 25 | 7.6% | 1.4% | ||
| Q4 24 | 5.3% | 1.1% | ||
| Q3 24 | 6.5% | 2.9% | ||
| Q2 24 | 5.1% | 1.2% |
| Q1 26 | 1.48× | — | ||
| Q4 25 | 1.39× | -18.08× | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.38× | 54.42× | ||
| Q3 24 | 0.96× | — | ||
| Q2 24 | 0.25× | -94.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
REGN
| Sanofi | $1.6B | 45% |
| Other | $507.0M | 14% |
| EYLEA - U.S | $473.0M | 13% |
| Bayer | $287.0M | 8% |
| Libtayo ® - U.S | $286.0M | 8% |
| Other revenue | $171.0M | 5% |
| Libtayo - ROW* | $152.0M | 4% |
| Praluent - U.S | $67.0M | 2% |
| Evkeeza ® - U.S | $46.0M | 1% |
| Lynozyfic ® - Global | $11.0M | 0% |
RKT
| Other | $1.4B | 51% |
| Direct To Customer Segment | $945.8M | 35% |
| Partner Network Segment | $216.7M | 8% |
| Subscription Revenue | $91.3M | 3% |
| Closing Fees | $47.1M | 2% |
| Appraisal Revenue | $10.7M | 0% |
